Botulinum Toxin in Raynaud's Phenomenon

PHASE4RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 10, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Raynaud Phenomenon
Interventions
DRUG

Botulinum toxin

Botulinum toxin is a neurotoxic protein produced by the bacterium Clostridium botulinum that prevents the release of the neurotransmitter acetylcholine from the neuromuscular junction, thereby preventing muscular contraction. Eligible subjects will be randomized 1:1:1 into three different groups: 1) placebo 2) 10 Units of BT injected per digit and 3) 20 units of BT injected per digit.

Trial Locations (1)

30322

RECRUITING

Emory University Hospital, Atlanta

All Listed Sponsors
collaborator

American Society for Surgery of the Hand

OTHER

lead

Emory University

OTHER

NCT05125029 - Botulinum Toxin in Raynaud's Phenomenon | Biotech Hunter | Biotech Hunter